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For the past few decades, there has been a considerable research interest in the area of drug 
delivery using particulate delivery systems as carriers for small and large molecules. 
Particulate systems like nanoparticles have been used as a physical approach to alter and 
improve the pharmacokinetic and pharmacodynamic properties of various types of drug 
molecules. They have been used in vivo to protect the drug entity in the systemic circulation, 
restrict access of the drug to the chosen sites and to deliver the drug at a controlled and 
sustained rate to the site of action. Various polymers have been used in the formulation of 
nanoparticles for drug delivery research to increase therapeutic benefit, while minimizing side 
effects. Here, we review various aspects of nanoparticle formulation, characterization, effect 
of their characteristics and their applications in delivery of drug molecules and therapeutic 
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INTRODUCTION 
 
Nanoparticles are defined as particulate 
dispersions or solid particles with a size in the 
range of 10-1000nm. The drug is dissolved, 
entrapped, encapsulated or attached to a 
nanoparticle matrix. Depending upon the method 
of preparation, nanoparticles, nanospheres or 
nanocapsules can be obtained. Nanocapsules 
are systems in which the drug is confined to a 
cavity surrounded by a unique polymer 
membrane, while nanospheres are matrix 
systems in which the drug is physically and 
uniformly dispersed. In recent years, 
biodegradable polymeric nanoparticles, 
particularly those coated with hydrophilic 
polymer such as poly(ethylene glycol) (PEG) 
known as long-circulating particles, have been 
used as potential drug delivery devices because 
of their ability to circulate for a prolonged period 
time target a particular organ, as carriers of DNA 
in gene therapy, and their ability to deliver 
proteins, peptides and genes 1-4.  
 
The major goals in designing nanoparticles as a 
delivery system are to control particle size, 
surface properties and release of 
pharmacologically active agents in order to 
achieve the site-specific action of the drug at the 
therapeutically optimal rate and dose regimen. 
Though liposomes have been used as potential 
carriers with unique advantages including 
protecting drugs from degradation, targeting to 
site of action and reduction toxicity or side 
effects, their applications are limited due to 
inherent problems such as low encapsulation 
efficiency, rapid leakage of water-soluble drug in 
the presence of blood components and poor 
storage stability. On the other hand, polymeric 
nanoparticles offer some specific advantages 
over liposomes. For instance, they help to 
increase the stability of drugs/proteins and 
possess useful controlled release properties 5, 6. 
The advantages of using nanoparticles as a drug 
delivery system include the following: 
1. Particle size and surface characteristics of 
nanoparticles can be easily manipulated to 
achieve both passive and active drug targeting 
after parenteral administration. 
2. They control and sustain release of the drug 
during the transportation and at the site of 
localization, altering organ distribution of the 
drug and subsequent clearance of the drug so 
as to achieve increase in drug therapeutic 
efficacy and reduction in side effects.  
 
3. Controlled release and particle degradation 
characteristics can be readily modulated by the 
choice of matrix constituents. 
Drug loading is relatively high and drugs can be 
incorporated into the systems without any 
chemical reaction; this is an important factor for 
preserving the drug activity. 
 
4.  Site-specific targeting can be achieved by 
attaching targeting ligands to surface of particles 
or use of magnetic guidance. 
 
5.   The system can be used for various routes of 
administration including oral, nasal, parenteral, 
intra-ocular etc. 
 
In spite of these advantages, nanoparticles do 
have limitations. For example, their small size 
and large surface area can lead to particle-
particle aggregation, making physical handling of 
nanoparticles difficult in liquid and dry forms. In 
addition, small particles size and large surface 
area readily result in limited drug loading and 
burst release. These practical problems have to 
be overcome before nanoparticles can be used 
clinically or made commercially available. The 
present review details the latest development of 
nanoparticulate drug delivery systems, surface 
modification issues, drug loading strategies, 
release control and potential applications of 
nanoparticles. 
 
Preparation of Nanoparticles 
Nanoparticles can be prepared from a variety of 
materials such as proteins, polysaccharides and 
synthetic polymers. The selection of matrix 
materials is dependent on many factors 
including7: (a) size of nanoparticles required; (b) 
inherent properties of the drug, e.g., aqueous 
solubility and stability; (c) surface characteristics 
such as charge and permeability; (d) degree of 
biodegradability, biocompatibility and toxicity; (e) 
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Drug release profile desired; and (f) Antigenicity 
of the final product. 
 
Nanoparticles have been prepared most 
frequency by three methods: (1) dispersion of 
preformed polymers; (2) polymerization of 
monomers; and (3) ionic gelation or coacervation 
of hydrophilic polymers. However, other methods 
such as supercritical fluid technology 8 and 
particle replication in non-wetting templates 
(PRINT) 9 have also been described in the 
literature for production of nanoparticles.  The 
latter was claimed to have absolute control of 
particle size, shape and composition, which 
could set an example for the future mass 
production of nanoparticles in industry.   
 
Dispersion of preformed polymers: Dispersion of 
preformed polymers is a common technique  
used to prepare biodegradable nanoparticles 
from poly (lactic acid) (PLA); poly (D,L-glycolide), 
PLG; poly (D, L-lactide-co-glycolide) (PLGA) and 
poly (cyanoacrylate) (PCA), 10-12. This technique 
can be used in various ways as described below. 
 
Solvent evaporation method: In this method, the 
polymer is dissolved in an organic solvent such 
as dichloromethane, chloroform or ethyl acetate 
which is also used as the solvent for dissolving 
the hydrophobic drug. The mixture of polymer 
and drug solution is then emulsified in an 
aqueous solution containing a surfactant or 
emulsifying agent to form an oil in water (o/w) 
emulsion. After the formation of stable emulsion, 
the organic solvent is evaporated either by 
reducing the pressure or by continuous stirring. 
Particle size was found to be influenced by the 
type and concentrations of stabilizer, 
homogenizer speed and polymer concentration 
13. In order to produce small particle size, often a 
high-speed homogenization or ultrasonication 
may be employed 14.  
 
Spontaneous emulsification or solvent diffusion 
method:This is a modified version of solvent 
evaporation method 15. In this method, the water-
miscible solvent along with a small amount of the 
water immiscible organic solvent is used as an 
oil phase. Due to the spontaneous diffusion of 
solvents an interfacial turbulence is created 
between the two phases leading to the formation 
of small particles. As the concentration of water 
miscible solvent increases, a decrease in the 
size of particle can be achieved. 
 
Both solvent evaporation and solvent diffusion 
methods can be used for hydrophobic or 
hydrophilic drugs. In the case of hydrophilic 
drug, a multiple w/o/w emulsion needs to be 
formed with the drug dissolved in the internal 
aqueous phase.     
 
Polymerization method 
In this method, monomers are polymerized to 
form nanoparticles in an aqueous solution . Drug 
is incorporated either by being dissolved in the 
polymerization medium or by adsorption onto the 
nanoparticles after polymerization completed. 
The nanoparticle suspension is then purified to 
remove various stabilizers and surfactants 
employed for polymerization by ultra-
centrifugation and  re-suspending the particles in 
an isotonic surfactant-free medium. This 
technique has been reported for making 
polybutylcyanoacrylate or poly 
(alkylcyanoacrylate)  nanoparticles16;17.  
Nanocapsule formation and their particle size 
depends on the concentration of the surfactants 
and stabilizers used 18. 
 
Coacervation or ionic gelation method 
Much research has been focused on the 
preparation of nanoparticles using biodegradable 
hydrophilic polymers such as chitosan, gelatin 
and sodium alginate. Calvo and co-workers 
developed a method for preparing hydrophilic 
chitosan nanoparticles by ionic gelation 19, 20. 
The method involves a mixture of two aqueous 
phases, of which one is the polymer chitosan, a 
di-block co-polymer ethylene oxide or propylene 
oxide (PEO-PPO) and the other is a polyanion 
sodium tripolyphosphate. In this method, 
positively charged amino group of chitosan 
interacts with negative charged tripolyphosphate 
to form coacervates with a size in the range of 
nanometer. Coacervates are formed as  a result 
of electrostatic interaction between two aqueous 
phases, whereas, ionic gelation involves the 
material undergoing transition from liquid to gel 
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due to ionic interaction conditions at room 
temperature. 
 
Production of nanoparticles using 
supercritical fluid technology 
Conventional methods such as solvent 
extraction-evaporation, solvent diffusion and 
organic phase separation methods require the 
use of organic solvents which are hazardous to 
the environment as well as to physiological 
systems. Therefore, the supercritical fluid 
technology has been investigated as an 
alternative to prepare biodegradable micro- and 
nanoparticles because supercritical fluids are 
environmentally safe 21.  
 
A supercritical fluid can be generally defined as 
a solvent at a temperature above its critical 
temperature, at which the fluid remains a single 
phase regardless of pressure 21. Supercritical 
CO2 (SC CO2) is the most widely used 
supercritical fluid because of its mild critical 
conditions (Tc = 31.1 °C, Pc = 73.8 bars), non-
toxicity, non-flammability, and low price. The 
most common processing techniques involving 
supercritical fluids are supercritical anti-solvent 
(SAS) and rapid expansion of critical solution 
(RESS).  The process of SAS employs a liquid 
solvent, eg methanol, which is completely 
miscible with the supercritical fluid (SC CO2), to 
dissolve the solute to be micronized; at the 
process conditions, because the solute is 
insoluble in the supercritical fluid, the extract of 
the liquid solvent by supercritical fluid leads to 
the instantaneous precipitation of the solute, 
resulting the formation of nanoparticles 8. Thote 
and Gupta (2005) reported the use of a modified 
SAS method for formation of hydrophilic drug 
dexamethasone phosphate drug nanoparticles 
for microencapsulation purpose 22.  
 
RESS differs from the SAS process in that its 
solute is dissolved in a supercritical fluid (such 
as supercritical methanol) and then the solution 
is rapidly expanded through a small nozzle into a 
region lower pressure 21 , Thus the solvent 
power of supercritical fluids dramatically 
decreases and the solute eventually precipitates. 
This technique is clean because the precipitate 
is basically solvent free. RESS and its modified 
process have been used for the product of 
polymeric nanoparticles 23. Supercritical fluid 
technology technique, although environmentally 
friendly and suitable for mass production, 
requires specially designed equipment and is 
more expensive.  
 




Particle size and size distribution are the most 
important characteristics of nanoparticle 
systems. They determine the in vivo distribution, 
biological fate, toxicity and the targeting ability of 
nanoparticle systems. In addition, they can also 
influence the drug loading, drug release and 
stability of nanoparticles.  
Many studies have demonstrated that 
nanoparticles of sub-micron size have a number 
of advantages over microparticles as a drug 
delivery system 24. Generally nanoparticles have 
relatively higher intracellular uptake compared to 
microparticles and available to a wider range of 
biological targets due to their small size and 
relative mobility.  Desai et al found that 100 nm 
nanoparticles had a 2.5 fold greater uptake than 
1 µm microparticles, and 6 fold greater uptake 
than 10 µm microparticles in a Caco-2 cell line25. 
In a subsequent study 26, the nanoparticles 
penetrated throughout the submucosal layers in 
a rat in situ intestinal loop model, while 
microparticles were predominantly localized in 
the epithelial lining. It was also reported that 
nanoparticles can across the blood-brain barrier 
following the opening of tight junctions by hyper 
osmotic mannitol, which may provide sustained 
delivery of therapeutic agents for difficult-to-treat 
diseases like brain tumors 27. Tween 80 coated 
nanoparticles have been shown to cross the 
blood-brain barrier 28. In some cell lines, only 
submicron nanoparticles can be taken up 
efficiently but not the larger size microparticles 
29. 
Drug release is affected by particle size. Smaller 
particles have larger surface area, therefore, 
most of the drug associated would be at or near 
the particle surface, leading to fast drug release. 
Whereas, larger particles have large cores which 
allow more drug to be encapsulated and slowly 
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diffuse out 30. Smaller particles also  have 
greater risk of aggregation of particles during 
storage and transportation of nanoparticle 
dispersion. It is always a challenge to formulate 
nanoparticles with the smallest size possible but 
maximum stability.   
Polymer degradation can also be affected by the 
particle size. For instance, the rate of PLGA 
polymer degradation was found to increase with 
increasing particle size in vitro 31. It was thought 
that in smaller particles, degradation products of 
PLGA formed can diffuse out of the particles 
easily while in large particles, degradation 
products are more likely remained within the 
polymer matrix for a longer period to cause 
autocatalytic degradation of the polymer 
material. Therefore, it was hypothesized that 
larger particles will contribute to faster polymer 
degradation as well as the drug release. 
However, Panyam et al prepared PLGA particles 
with different size ranges and found that the 
polymer degradation rates in vitro were not 
substantially different for different size particles 
32.  
Currently, the fastest and most routine method of 
determining particle size is by photon-correlation 
spectroscopy or dynamic light scattering. 
Photon-correlation spectroscopy requires the 
viscosity of the medium to be known and 
determines the diameter of the particle by 
Brownian motion and light scattering properties 
33. The results obtained by photon-correlation 
spectroscopy are usually verified by scanning or 
transmission electron microscopy (SEM or 
TEM). 
 
Surface properties of nanoparticles 
When nanoparticles are administered 
intravenously, they are easily recognized by the 
body immune systems, and are then cleared by 
phagocytes from the circulation 34. Apart from 
the size of nanoparticles, their surface 
hydrophobicity determines the amount of 
adsorbed blood components, mainly proteins 
(opsonins). This in turn influences the in vivo fate 
of nanoparticles 34, 35. Binding of these opsonins 
onto the surface of nanoparticles called 
opsonization acts as a bridge between 
nanoparticles and phagocytes. The association 
of a drug to conventional carriers leads to 
modification of the drug biodistribution profile, as 
it is mainly delivered to the mononuclear 
phagocytes system (MPS) such as liver, spleen, 
lungs and bone marrow. Indeed, once in the 
blood stream, surface non-modified 
nanoparticles (conventional nanoparticles) are 
rapidly opsonized and massively cleared by the  
macrophages of MPS rich organs 36. Generally, 
it is IgG, compliment C3 components that are 
used for recognition of foreign substances, 
especially foreign macromolecules.   
   
Hence, to increase the likelihood of the success 
in drug targeting by nanoparticles, it is necessary 
to minimize the opsonization and to prolong the 
circulation of nanoparticles in vivo. This can be 
achieved by (a) surface coating of nanoparticles 
with hydrophilic polymers/surfactants; (b) 
formulation of nanoparticles with biodegradable 
copolymers with hydrophilic segments such as 
polyethylene glycol (PEG), polyethylene oxide, 
polyoxamer, poloxamine and polysorbate 80 
(Tween 80).   
 
Studies show that PEG conformation at the 
nanoparticle surface is of utmost importance for 
the opsonin repelling function of the PEG layer. 
PEG surfaces in brush-like and intermediate 
configurations reduced phagocytosis and 
complement activation whereas PEG surfaces in 
mushroom-like configuration were potent 
complement activators and favoured 
phagocytosis 2, 37.  
 
The zeta potential of a nanoparticle is commonly 
used to characterise the surface charge property 
of nanoparticles 38. It reflects the electrical 
potential of particles and is influenced by the 
composition of the particle and the medium in 
which it is dispersed. Nanoparticles with a zeta 
potential above (+/-) 30 mV have been shown to 
be stable in suspension, as the surface charge 
prevents aggregation of the particles. The zeta 
potential can also be used to determine whether 
a charged active material is encapsulated within 
the centre of the nanocapsule or adsorbed onto 
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Drug loading 
Ideally, a successful nanoparticulate system 
should have a high drug-loading capacity 
thereby reduce the quantity of matrix materials 
for administration. Drug loading can be done by 
two methods:  
• Incorporating at the time of 
nanoparticles production (incorporation method)  
• Absorbing the drug after formation of 
nanoparticles by incubating the carrier with a 
concentrated drug solution (adsorption 
/absorption technique).  
Drug loading and entrapment efficiency very 
much depend on the solid-state drug solubility in 
matrix material or polymer (solid dissolution or 
dispersion), which is related to the polymer 
composition, the molecular weight, the drug 
polymer interaction and the presence of end-
functional groups (ester or carboxyl) 39 40 41. The 
PEG moiety has no or little effect on drug 
loading 42.  The macromolecule or protein shows 
greatest loading efficiency when it is loaded at or 
near its isoelectric point when it has minimum 
solubility and maximum adsorption 19 For small 
molecules, studies show the use of ionic 
interaction between the drug and matrix 
materials can be a very effective way to increase 
the drug loading 43, 44.  
 
Drug release 
To develop a successful nanoparticulate system, 
both drug release and polymer biodegradation 
are important consideration factors. In general, 
drug release rate depends on: (1) solubility of 
drug; (2) desorption of the surface-
bound/adsorbed drug; (3) drug diffusion through 
the nanoparticle matrix; (4) nanoparticle matrix 
erosion/degradation; and (5) combination of 
erosion/diffusion process. Thus solubility, 
diffusion and biodegradation of the matrix 
materials govern the release process. 
 
In the case of nanospheres, where the drug is 
uniformly distributed, the release occurs by 
diffusion or erosion of the matrix under sink 
conditions. If the diffusion of the drug is faster 
than matrix erosion, the mechanism of release is 
largely controlled by a diffusion process. The 
rapid initial release or ‘burst’ is mainly attributed 
to weakly bound or adsorbed drug to the large 
surface of nanoparticles 45. It is evident that the 
method of incorporation has an effect on release 
profile. If the drug is loaded by incorporation 
method, the system has a relatively small burst 
effect and better sustained release 
characteristics 46. If the nanoparticle is coated by 
polymer, the release is then controlled by 
diffusion of the drug from the core across the 
polymeric membrane. The membrane coating 
acts as a barrier to release, therefore, the 
solubility and diffusivity of drug in polymer 
membrane becomes determining factor in drug 
release. Furthermore release rate can also be 
affected by ionic interaction between the drug 
and addition of auxillary ingredients. When the 
drug is involved in  interaction with auxillary 
ingredients to form a less water soluble complex, 
then the drug release can be very slow with 
almost no burst release effect 43; whereas if the 
addition of auxillary ingredients e.g., addition of 
ethylene oxide-propylene oxide block copolymer 
(PEO-PPO)  to chitosan, reduces the interaction 
of the model drug bovine serum albumin (BSA) 
with the matrix material (chitosan) due to 
competitive electrostatic interaction of PEO-PPO 
with chitosan, then an increase in drug release 
could be observed 20.  
 
Various methods which can be used to study the 
in vitro release of the drug are: (1) side-by-side 
diffusion cells with artificial or biological 
membranes; (2) dialysis bag diffusion technique; 
(3) reverse dialysis bag technique; (4) agitation 
followed by ultracentrifugation/centrifugation; (5) 
Ultra-filtration or centrifugal ultra-filtration 
techniques. Usually the release study is carried 
out by controlled agitation followed by 
centrifugation. Due to the time-consuming nature 
and technical difficulties encountered in the 
separation of nanoparticles from release media, 
the dialysis technique is generally preferred.  
 
Applications of Nanoparticulate Delivery 
Systems 
 
Tumor targeting using nanoparticulate delivery 
systems 
The rationale of using nanoparticles for tumor 
targeting is based on 1) nanoparticles will be 
able to deliver a concentrate dose of drug in the 
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vicinity of the tumor targets via the enhanced 
permeability and retention effect or active 
targeting by ligands on the surface of 
nanoparticles; 2) nanoparticles will reduce the 
drug exposure of health tissues by limiting drug 
distribution to target organ. 
 
Verdun et al demonstrated in mice treated with 
doxorubicin incorporated into poly 
(isohexylcyanoacrylate) nanopsheres that higher 
concentrations of doxorubicin manifested in the 
liver, spleen and lungs than in mice treated with 
free doxorubicin 47. Studies show that the 
polymeric composition of nanoparticles such as 
type, hydrophobicity and biodegradation profile 
of the polymer along with the associated drug’s 
molecular weight, its localization in the 
nanospheres and mode of incorporation 
technique, adsorption or incorporation, have a 
great influence on the drug distribution pattern in 
vivo. The exact underlying mechanism is not 
fully understood but the biodistribution of 
nanoparticles is rapid, within ½ hour to 3 hours, 
and it likely involves MPS and 
endocytosis/phagocytosis process  48. 
 
Recently Bibby et al reported the biodistribution 
and pharmacokinetics (PK) of a cyclic RGD-
doxorubicin-nanoparticle formulation in tumor-
bearing mice 49. Their biodistribution studies 
revealed decreasing drug concentrations over 
time in the heart, lung, kidney and plasma and 
accumulating drug concentrations in the liver, 
spleen and tumor. The majority injected dose 
appeared in the liver (56%) and only 1.6% in the 
tumour at 48 hrs post injection, confirming that 
nanoparticles have a great tendency to be 
captured by liver. This indicates the greatest 
challenge of using nanoparticles for tumour 
targeting is to avoid particle uptake by 
mononuclear phagocytic system (MPS) in liver 
and spleen.        
Such propensity of MPS for 
endocytosis/phagocytosis of nanoparticles 
provides an opportunity to effectively deliver 
therapeutic agents to these cells. This 
biodistribution can be of benefit for the 
chemotherapeutic treatment of MPS- rich 
organs/tissues localized tumors like hepato-
carcinoma, hepatic metastasis arising from 
digestive tract or gynaecological cancers, 
brochopulmonary tumors, primitive tumors and 
metastasis, small cell tumors, myeloma and 
leukemia.  It has been proved that using 
doxorubicin loaded conventional nanoparticles 
was effective against hepatic metastasis model 
in mice. It was found there was greater reduction 
in the degree of metastasis than when free drug 
was used. The underlying mechanism 
responsible for the increased therapeutic 
efficacy of the formulation was transfer of 
doxorubicin from healthy tissue, acting as a drug 
reservoir to the malignant tissues 50. Histological 
examination showed a considerable 
accumulation of nanoparticles in the lysosomal 
vesicles of Kupffer cells, whereas nanoparticles 
could not be clearly identified in tumoral cells 50. 
Thus Kupffer cells, after a massive uptake of 
nanoparticles by phagocytosis, were able to 
induce the release of doxorubicin, leading to a 
gradient of drug concentration, favorable for a 
prolonged diffusion of the free and still active 
drug towards the neighboring metastatic cells 50.   
 
When conventional nanoparticles are used as 
carriers in chemotherapy, some cytotoxicity 
against the Kupffer cells can be expected, which 
would result in deficiency of Kupffer cells and 
naturally lead to reduced liver uptake and 
decreased therapeutic effect with intervals of 
less than 2 weeks administration 51. Moreover, 
conventional nanoparticles can also target bone 
marrow (MPS tissue), which is an important but 
unfavorable site of action for most anticancer 
drugs because chemotherapy with such carriers 
may increase myelosuppresive effect. Therefore, 
the ability of conventional nanoparticles to 
enhance anticancer drugs efficacy is limited to 
targeting tumors at the level of MPS-rich organs. 
Also, directing anticancer drug-loaded 
nanoparticles to other tumoral sites is not 
feasible if a rapid clearance of nanoparticles 
occurs shortly after intravenous administration. 
 
Long circulating nanoparticles 
To be successful as a drug delivery system, 
nanoparticles must be able to target tumors 
which are localized outside MPS-rich organs.  In 
the past decade, a great deal of work has been 
devoted to developing so-called “stealth” 
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particles or PEGylated nanoparticles, which are 
invisible to macrophages or phagocytes 52. A 
major breakthrough in the field came when the 
use of hydrophilic polymers (such as 
polyethylene glycol, poloxamines, poloxamers, 
and polysaccharides) to efficiently coat 
conventional nanoparticle surface produced an 
opposing effect to the uptake by the MPS 52, 53. 
These coatings provide a dynamic “cloud” of 
hydrophilic and neutral chains at the particle 
surface which repel plasma proteins 54 55. As a 
result, those coated nanoparticles become 
invisible to MPS, therefore, remained in the 
circulation for a longer period of time. Hydrophilic 
polymers can be introduced at the surface in two 
ways, either by adsorption of surfactants or by 
use of block or branched copolymers for 
production of nanoparticles 51, 52.  
 
Studies show nanoparticles containing a coat of 
PEG  not only have a prolonged half-life in the 
blood compartment but also be able to 
selectively extravasate in pathological sites such 
as tumors or inflamed regions with a leaky 
vasculature 51. As a result, such long-circulating 
nanoparticles have increased the potential to 
directly target tumors located outside MPS-rich 
regions 51. The size of the colloidal carriers as 
well as their surface characteristics are the 
critical to the biological fate of nanoparticles. A 
size less than 100 nm and a hydrophilic surface 
are essential in achieving the reduction of 
opsonisation reactions and subsequent 
clearance by macrophages 52. Coating 
conventional nanoparticles with surfactants or 
PEG to obtain a long-circulating carrier has now 
been used as a standard strategy for drug 
targeting in vivo.  
 
Extensive efforts have been devoted to 
achieving “active targeting” of nanoparticles in 
order to deliver drugs to the right targets, based 
on molecular recognition processes such as 
ligand-receptor or antigen-antibody interaction. 
Considering that fact that folate receptors are 
over expressed on the surface of some human 
malignant cells and the cell adhesion molecules 
such as selectins and integrins are involved in 
metastatic events, nanoparticles bearing specific 
ligands such as folate may be used to target 
ovarian carcinoma while specific peptides or 
carbohydrates may be used to target integrins 
and selectins 56.  Oyewumi et al demonstrated 
that the benefits of folate ligand coating were to 
facilitate tumor cell internalization and retention 
of Gd-nanoparticles in the tumor tissue 57. 
 
Targeting with small ligands appears more likely 
to succeed since they are easier to handle and 
manufacture. Furthermore, it could be 
advantageous when the active targeting ligands 
are used in combination with the long-circulating 
nanoparticles to maximize the likelihood of the 
success in active targeting of nanoparticles.    
 
Reversion of multidrug resistance in tumour 
cells 
Anticancer drugs, even if they are located in the 
tumour interstitium, can turn out to be of limited 
efficacy against numerous solid tumour types, 
because cancer cells are able to develop 
mechanisms of resistance 58. These 
mechanisms allow tumours to evade 
chemotherapy. Multidrug resistance (MDR) is 
one of the most serious problems in 
chemotherapy. MDR occurs mainly due to the 
over expression of the plasma membrane p-
glycoprotein (Pgp), which is capable of extruding 
various positively charged xenobiotics, including 
some anticancer drugs, out of cells 58. In order to 
restore the tumoral cells’ sensitivity to anticancer 
drugs by circumventing Pgp-mediated MDR, 
several strategies including the use of colloidal 
carriers  have been applied. The rationale 
behind the association of drugs with colloidal 
carriers, such as nanoparticles, against drug 
resistance derives from the fact that Pgp 
probably recognizes the drug to be effluxed out 
of the tumoral cells only when this drug is 
present in the plasma membrane, and not when 
it is located in the cytoplasm or lysosomes after 
endocytosis 59 60. 
 
Nanoparticles for oral delivery of peptides 
and proteins 
Significant advances in biotechnology and 
biochemistry have led to the discovery of a large 
number of bioactive molecules and vaccines 
based on peptides and proteins. Development of 
suitable carriers remains a challenge due to the 
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fact that bioavailability of these molecules is 
limited by the epithelial barriers of the 
gastrointestinal tract and their susceptibility to 
gastrointestinal degradation by digestive 
enzymes. Polymeric nanoparticles allow 
encapsulation of bioactive molecules and protect 
them against enzymatic and hydrolytic 
degradation. For instance, it has been found that 
insulin-loaded nanoparticles have preserved 
insulin activity and produced blood glucose 
reduction in diabetic rats for up to 14 days 
following the oral administration 61.  
 
The surface area of human mucosa extends to 
200 times that of skin 62. The gastrointestinal 
tract provides a variety of physiological and 
morphological barriers against protein or peptide 
delivery, e.g., (a) proteolytic enzymes in the gut 
lumen like pepsin, trypsin and chymotrypsin; (b) 
proteolytic enzymes at the brush border 
membrane (endopeptidases); (c) bacterial gut 
flora; and (d) mucus layer and epithelial cell 
lining itself 63. The histological architecture of the 
mucosa is designed to efficiently prevent uptake 
of particulate matter from the environment. One 
important strategy to overcome the 
gastrointestinal barrier is to deliver the drug in a 
colloidal carrier system, such as nanoparticles, 
which is capable of enhancing the interaction 
mechanisms of the drug delivery system and the 
epithelia cells in the GI tract. . 
 
Targeting of nanoparticles to epithelial cells 
in the GI tract using ligands 
Targeting strategies to improve the interaction of 
nanoparticles with adsorptive enterocytes and 
M-cells of Peyer’s patches in the GI tract can be 
classified into those utilizing specific binding to 
ligands or receptors and those based on non-
specific adsorptive mechanism. The surface of 
enterocytes and M cells display cell-specific 
carbohydrates, which may serve as binding sites 
to colloidal drug carriers containing appropriate 
ligands. Certain glycoproteins and lectins bind 
selectively to this type of surface structure by 
specific receptor-mediated mechanism. Different 
lectins, such as bean lectin and tomato lectin, 
have been studied to enhance oral peptide 
adsorption 64 65. Vitamin B-12 absorption from 
the gut under physiological conditions occurs via 
receptor-mediated endocytosis. The ability to 
increase oral bioavailability of various peptides 
(e.g., granulocyte colony stimulating factor, 
erythropoietin) and particles by covalent coupling 
to vitamin B-12 has been studied 66, 67. For this 
intrinsic process, mucoprotein is required, which 
is prepared by the mucus membrane in the 
stomach and binds specifically to cobalamin. 
The mucoprotein completely reaches the ileum 
where resorption is mediated by specific 
receptors. 
 
Absorption enhancement using non-specific 
interactions 
In general, the gastrointestinal absorption of 
macromolecules and particulate materials 
involves either paracellular route or endocytotic 
pathway. The paracellular route of absorption of 
nanoparticles utilises less than 1% of mucosal 
surface area. Using polymers such as chitosan 
68, starch 69 or poly(acrylate) 70 can increase the 
paracellular permeability of macromolecules. 
Endocytotic pathway for absorption of 
nanoparticles is either by receptor-mediated 
endocytosis, that is, active targeting, or 
adsorptive endocytosis which does not need any 
ligands. This process is initiated by an unspecific 
physical adsorption of material to the cell surface 
by electrostatic forces such as hydrogen bonding 
or hydrophobic interactions 71. Adsorptive 
endocytosis depends primarily on the size and 
surface properties of the material. If the surface 
charge of the nanoparticles is positive or 
uncharged, it will provide an affinity to adsorptive 
enterocytes though hydrophobic, whereas if it is 
negatively charged and hydrophilic, it shows 
greater affinity to adsorptive enterocytes and M-
cells. This shows that a combination of size, 
surface charge and hydrophilicity play a major 
role in affinity. This is demonstrated with poly 
(styrene) nanoparticles and when it is 
carboxylated 72.  
 
Nanoparticles for gene delivery 
Polynucleotide vaccines work by delivering 
genes encoding relevant antigens to host cells 
where they are expressed, producing the 
antigenic protein within the vicinity of 
professional antigen presenting cells to initiate 
immune response. Such vaccines produce both 
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humoral and cell-mediated immunity because 
intracellular production of protein, as opposed to 
extracellular deposition, stimulates both arms of 
the immune system 73. The key ingredient of 
polynucleotide vaccines, DNA, can be produced 
cheaply and has much better storage and 
handling properties than the ingredients of the 
majority of protein-based vaccines. Hence, 
polynucleotide vaccines are set to supersede 
many conventional vaccines particularly for 
immunotherapy. However, there are several 
issues related to the delivery of polynucleotides 
which limit their application. These issues 
include efficient delivery of the polynucleotide to 
the target cell population and its localization to 
the nucleus of these cells, and ensuring that the 
integrity of the polynucleotide is maintained 
during delivery to the target site. 
  
Nanoparticles loaded with plasmid DNA could 
also serve as an efficient sustained release gene 
delivery system due to their rapid escape from 
the degradative endo-lysosomal compartment to 
the cytoplasmic compartment 74. Hedley et al. 75 
reported that following their intracellular uptake 
and endolysosomal escape, nanoparticles could 
release DNA at a sustained rate resulting in 
sustained gene expression. This gene delivery 
strategy could be applied to facilitate bone 
healing by using PLGA nanoparticles containing 
therapeutic genes such as bone morphogenic 
protein.  
 
Nanoparticles for drug delivery into the brain   
The blood-brain barrier (BBB) is the most 
important factor limiting the development of new 
drugs for the central nervous system. The BBB 
is characterized by relatively impermeable 
endothelial cells with tight junctions, enzymatic 
activity and active efflux transport systems. It 
effectively prevents the passage of water-soluble 
molecules from the blood circulation into the 
CNS, and can also reduce the brain 
concentration of lipid-soluble molecules by the 
function of enzymes or efflux pumps 76. 
Consequently, the BBB only permits selective 
transport of molecules that are essential for brain 
function. 
 
Strategies for nanoparticle targeting to the brain 
rely on the presence of and nanoparticle 
interaction with specific receptor-mediated 
transport systems in the BBB. For example 
polysorbate 80/LDL, transferrin receptor binding 
antibody (such as OX26), lactoferrin, cell-
penetrating peptides and melanotransferrin have 
been shown capable of delivery of a self non 
transportable drug into the brain via the chimeric 
construct that can undergo receptor-mediated 
transcytosis 77-81. It has been reported 
poly(butylcyanoacrylate) nanoparticles was able 
to deliver hexapeptide dalargin, doxorubicin and 
other agents into the brain which is significant 
because of the great difficulty for drugs to cross 
the BBB 77. Despite some reported success with 
polysorbate 80 coated NPs, this system does 
have many shortcomings including desorption of 
polysorbate coating, rapid NP degradation and 
toxicity caused by presence of high 
concentration of polysorbate 80.37. OX26 MAbs 
(anti-transferrin receptor MAbs), the most 
studied BBB targeting antibody, have been used 
to enhance the BBB penetration of lipsosomes 
82. However, recently, Ji et al. demonstrated that 
brain uptake of lactoferrin, an iron-binding 
glycoprotein belonging to the transferrin (Tf) 
family, is twice that of OX26 and transferrrin in 
vivo 79. It is possible soon we will see these BBB 
specific molecules used for targeting 
nanoparticles to the brain.  
 
CONCLUSION 
The foregoing show that nanoparticulate 
systems have great potentials, being able to 
convert poorly soluble, poorly absorbed and 
labile biologically active substance into 
promising deliverable drugs. The core of this 
system can enclose a variety of drugs, enzymes, 
genes and is characterized by a long circulation 
time due to the hydrophilic shell which prevents 
recognition by the reticular-endothelial system. 
To optimize this drug delivery system, greater 
understanding of the different mechanisms of 
biological interactions, and particle engineering, 
is still required. Further advances are needed in 
order to turn the concept of nanoparticle 
technology into a realistic practical application as 
the next generation of drug delivery system. 
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